Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type abstract
PMID
Authors Maria Vieito; Elisa Fontana; Catherine Han; Eduardo Castanon; David J Pinato; Oliver Bechter; Irene Moreno; Rikke L Eefsen; Ruth Plummer; Reinhard Dummer; Hans Prenen; Giulia Pretelli; Gabriel Schnetzler; Piergiorgio Pettazzoni; Abiraj Keelara; David Dejardin; Andreas Roller; Ernesto Guarin; Elisa Cinato; Tomi Fakolade; Nino Keshelava; Ting Liu; Nick Flinn; Nicole A. Kratochwil
Title Abstract CT017: A phase I study evaluating safety, pharmacokinetics, and clinical activity of the novel, paradox breaker BRAF inhibitor RG6344 in patients with BRAF V600-mutant solid tumors
Journal Vol Issue Date Pages Journal Short Title
Cancer Research 85 8_Supplement_2 April 15, 2025
URL https://aacrjournals.org/cancerres/article/85/8_Supplement_2/CT017/761335/Abstract-CT017-A-phase-I-study-evaluating-safety
Abstract Text Background: Clinical benefit of first generation BRAF inhibitors (BRAFi) as monotherapy is limited due to paradoxical feedback activation of downstream MAPK or EGFR; combinations with MEK inhibitors (in melanoma) or EGFR antibodies (in colorectal cancer [CRC]) have become a standard of care in BRAF V600-mutant tumors. RG6344 (RO7276389) is a novel brain penetrant paradox breaker BRAFi designed to address the limitations of approved BRAFi. Methods: Dose escalation of RG6344, as a single agent and in combination with standard dose of cobimetinib, is being conducted in participants with solid tumors harboring a BRAF V600E mutation up to the protocol specified maximum daily dose. The objectives were to define the maximum tolerated dose (MTD), the recommended Phase 2 dose and additionally to characterize safety, PK/PD, and clinical outcomes (ISRCTN13713551). Results: As of December 5, 2024, 66 patients (56% with prior BRAFi treatment), including 7 patients with non-measurable brain lesions, have been treated with RG6344 in the monotherapy dose escalation part of the study and 12 patients in the combination part with cobimetinib including 5 patients with measurable and one with non-measurable brain lesions. Eleven melanoma, 51 CRC, 4 patients with other cancers received at least one dose of study drug as a single agent (dose escalation in combination still ongoing and not reported). One dose limiting toxicity event of grade 3 rash maculo-papular was reported. MTD has not been reached up to the highest daily dose of 3600 mg. Grade 3 treatment-related AEs (TRAEs) occurred in 11 patients (16.6 %), grade 4 TRAEs in 2 patients (3%; both laboratory findings) and no grade 5 TRAEs were reported. 2 patients (3%) discontinued study treatment due to TRAEs. None of the known BRAFi class toxicities, such as cutaneous squamous cell carcinomas, including Palmar-Plantar Erythrodysesthesia (PPE) and keratoacanthoma, have been observed to date. Linear and time-independent PK was demonstrated across the tested dose range, reaching Ctrough levels exceeding PK-derived pERK inhibition >90%. Exposure -response (metabolic responses measured with FDG-PET) relationship was observed. Objective response rate (ORR) was 25% in a total of 64 evaluable patients across tumor types and doses including patients with brain metastases and/or refractory to or relapsing on prior BRAFi treatment. Conclusions: RG6344 is well tolerated allowing unprecedented exposure for pERK inhibition and shows promising preliminary activity.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
RG6344 RG6344 2 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
RG6344 RO7276389|RG-6344|RG 6344|RO-7276389|RO 7276389 BRAF Inhibitor 26 RG6344 is a paradox-breaking BRAF inhibitor, which potentially decreases tumor growth (Cancer Res (2025) 85 (8_Supplement_2): CT017).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600E melanoma predicted - sensitive RG6344 Case Reports/Case Series Actionable In a Phase I trial, RG6344 treatment was well tolerated and demonstrated preliminary activity in patients with advanced solid tumors harboring BRAF V600E (n=64), including melanoma (n=11) and colorectal cancer (n=51), with an objective response rate of 25% (Cancer Res (2025) 85 (8_Supplement_2): CT017). detail...
BRAF V600E colorectal cancer predicted - sensitive RG6344 Phase I Actionable In a Phase I trial, RG6344 treatment was well tolerated and demonstrated preliminary activity in patients with advanced solid tumors harboring BRAF V600E (n=64), including melanoma (n=11) and colorectal cancer (n=51), with an objective response rate of 25% (Cancer Res (2025) 85 (8_Supplement_2): CT017). detail...